Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World November 10, 2015 Hepeng Jia	China's first science Nobel prize exposes anxiety on research Artemisinin saves tens of thousands of lives every year. The story of its discovery has been debated for decades in China. The awarding of the medicine Nobel prize has only served to reopen old wounds.
Chemistry World April 25, 2008 James Mitchell Crow	Drug Costs Cut on World Malaria Day Swiss pharmaceuticals firm Novartis has announced it will reduce by one fifth the price it charges governments and NGOs for artemisinin-based antimalarial Coartem.
Chemistry World May 2007 Lisa Melton	Chinese Medicine in Western Packaging The past decade has seen a global awakening to the truly curative powers of many ancient medicines, from black bear bile to the Asian plant Epimedium.
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
BusinessWeek January 17, 2005 Einhorn & Kripalani	Wanted: New Weapons Against An Old Killer Many of the new malaria medicines are in early stages of development. But with tsunami-hit countries receiving billions in aid there may finally be both the will and the means to tackle one of the world's most dangerous diseases.
Chemistry World April 17, 2013 Mark Peplow	Sanofi launches malaria drug production On 11 April, the Paris-based pharmaceutical company Sanofi officially launched a new production facility in Garessio, Italy, to make artemisinin -- the precursor to artemisinin-based combination therapies, the most effective drugs against the deadliest malaria parasite.
Chemistry World April 2008 Victoria Gill	Malaria no More? A fresh round of research funding could put an end to the killer disease.
Chemistry World May 3, 2012 Akshat Rathi	Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years.
Fast Company September 2006 Tonya Garcia	Miracle Microbes In the labs of Amyris Biotechnologies, molecular manipulation may yield cheap and effective malaria drugs.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
Chemistry World October 5, 2015 Matthew Gunther	Antiparasitic drugs derived from natural products take 2015 medicine Nobel The 2015 Nobel prize in physiology or medicine has been split between three researchers for unearthing two naturally-occurring antimicrobial products that can fight parasitic diseases such as malaria and river blindness.
Chemistry World April 25, 2007 Richard Van Noorden	Malaria Drug Cures Mice with Single Dose U.S. chemists have adapted a Chinese herbal medicine to create a new generation of antimalarial drugs which could solve some of the current crop's failings.
Chemistry World April 10, 2013 Hayley Birch	Yeast to make malaria drug on demand A natural biochemical pathway that produces the antimalarial drug artemisinin in the sweet wormwood plant has been fully reconstructed in yeast.
Scientific American October 2007 Jeffrey D. Sachs	Ending Malaria Deaths in Africa One of the world s worst killers can be stopped soon if we make the investment.
Chemistry World September 10, 2014 Elisabeth Ratcliffe	Antimalarial flow synthesis closer to commercialization Scientists in Germany have demonstrated the large scale and inexpensive production of a range of antimalarial drugs, using a continuous flow system.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool November 6, 2006 Brian Gorman	Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
Scientific American September 2007 Jeffrey D. Sachs	Ending Malaria Deaths in Africa One of the world's worst killers can be stopped soon if we make the investment.
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
Chemistry World May 20, 2015 Andy Extance	Malaria drug could cash in on green chemistry Green chemistry principles could make synthesizing the frontline antimalarial drug artemisinin both cleaner and cheaper, an industry -- academia collaboration suggests.
The Motley Fool April 22, 2008 Brian Lawler	No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
Chemistry World January 20, 2012 Andy Extance	Tube-wrapped lamp makes malaria drug German researchers have developed an inexpensive three-step continuous flow synthesis of artemisinin, the key drug in the ongoing fight against malaria.
The Motley Fool April 25, 2007 Brian Lawler	Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.
Entrepreneur January 2008 Chris Penttila	Can You Compete? Chinese manufacturers aren't just making your stuff - they're making their own, too.
Bio-IT World November 2005 Mark D. Uehling	The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry.
Pharmaceutical Executive March 12, 2012 William Looney	Novartis: LEADing in Emerging Markets With growth as its guiding light, Novartis has big plans for the emerging markets. CEO Joe Jimenez tells us what it will take the company to best the competition.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool February 5, 2008 Will Frankenhoff	3 Reasons to Stay in Chinese Stocks in 2008 The recent savage sell-off in Chinese stocks -- the Shanghai index has fallen more than 13% since the beginning of the year -- may represent a buying opportunity.